Will HD resume share buybacks by end of Q2 FY2026 (August 2026)?

Management explicitly guided buyback resumption for 'first half of 2027' (calendar), which maps to Q4 FY2026-Q1 FY2027. This market resolves on Q1-Q2 FY2026, ending August 2026 — a full 6 months before the guided timeline. With $1.4B cash, $50.4B net debt, and only $3.4B/year available for deleveraging after $9.2B in dividends, management has neither the financial flexibility nor the stated intention to resume buybacks this early. The buyback pause is step 1 in the 'what breaks first' cascade and no lens suggests early resumption is plausible. The only scenario where this resolves YES is a dramatic positive surprise — rapid EBITDA growth, asset sales, or a complete reversal of stated capital allocation priorities — which would be historically unusual for HD.

The temporal mismatch is the dominant factor — this market asks about H1 FY2026 (ending Aug 2026) while management guides H1 2027 calendar (Jan-Jun 2027). However, I assign slightly higher probability than a pure 'management always follows guidance' base rate because of the ambiguity the committee identified: if the buyback pause is 'discipline' (Opus view) rather than 'forced constraint' (Sonnet view), management could accelerate if EBITDA surprises upward from SRS integration synergies. HD's operating cash flow of $16.3B is substantial, and if integration costs come in below plan, there could be a token buyback as early as Q2 FY2026 as a confidence signal. But even in this optimistic scenario, the $1.4B cash position and the need to build an 'excess cash position' before resumption makes it unlikely within the resolution window.

Examining the deleveraging math: with ~$3.4B available annually after dividends and capex, HD could potentially reduce net debt by ~$1.7B in the first half of FY2026. Starting from $50.4B net debt, that brings them to ~$48.7B — still enormous relative to the pre-acquisition level. Management targets an 'excess cash position' before resumption, meaning they need to both delever AND build a cash buffer. From $1.4B, accumulating meaningful excess cash while servicing $51.8B in debt is a multi-quarter project. The interest coverage at 9.1x is comfortable but not so strong as to create room for discretionary capital return ahead of schedule. SRS integration costs represent additional downside risk to the timeline. The probability of any buyback activity in Q1 or Q2 FY2026 is very low.

This is straightforward. Management said H1 2027 calendar. The market asks about H1 FY2026, which ends August 2026. That is 5-6 months before the earliest point in the guided window. HD has $1.4B cash, $50.4B net debt, and $9.2B in annual dividends consuming 56% of OCF. They have zero financial reason and zero stated intention to resume buybacks in Q1 or Q2 FY2026. The Stress Scanner classifies FUNDING_FRAGILITY as STRETCHED. The committee found no lens suggesting early resumption. This is a low-probability event — essentially requiring management to contradict their own recent guidance.

The buyback is clearly step 1 in the 'what breaks first' cascade — it is already broken. Management paused buybacks entirely in FY2025 after deploying ~$24B on acquisitions. Resuming buybacks 6 months ahead of guidance would be a dramatic reversal of capital allocation strategy that would raise questions about why they guided H1 2027 in the first place. From a corporate governance perspective, contradicting a recent guidance timeline this quickly would undermine management credibility. The only plausible scenario is a tiny token buyback for stock-based compensation offset, but even that seems unlikely given the explicit pause and the language around needing an 'excess cash position' first.

I give this slightly more than 5% because there is a non-zero scenario where HD's Q1 FY2026 results (Feb-Apr 2026) show substantially better-than-expected OCF from SRS synergies or housing recovery, and management signals a pull-forward of the buyback timeline in the Q1 earnings call (likely June 2026). If they announced a small ASR or open market program starting in Q2 FY2026 (May-Jul), that would resolve YES. But this requires: (1) EBITDA surprise well above consensus, (2) management willingness to contradict 2-month-old guidance, (3) sufficient cash accumulation in a single quarter. The conjunction of all three is improbable. Housing market conditions remain frozen and SRS integration is early-stage.

Management guided H1 2027 for buyback resumption. Market asks about H1 FY2026 — 6 months too early. Cash is $1.4B, debt is $50.4B. No financial room and no stated intent to resume early. Very low probability.

Buybacks are completely paused and management explicitly guides resumption for H1 2027. With $50.4B in net debt and only $3.4B/year for deleveraging, resuming 6 months early would be financially irresponsible. The base rate for large-cap companies contradicting a recent specific capital allocation guidance this quickly is very low.

The timing gap is decisive. Management's H1 2027 calendar guidance is specific and recent (Q4 FY2025 earnings call, Feb 2026). Resuming in Q1-Q2 FY2026 would mean starting buybacks within weeks to months of giving that guidance. Highly unlikely absent an extraordinary catalyst like a major asset sale or unexpected windfall.